Correction to : Cardiovascular Drugs and Therapy
https://doi.org/10.1007/s10557-021-07291-y
The original article has been corrected. References 5 and 6 have been switched. Reference 5 “Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and worsening heart failure. N Eng J Med. 2021;384:117–28” should be “Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Eng J Med. 2021;384:129–39.” Reference 6 “Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Eng J Med. 2021;384:129–39” should be “Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and worsening heart failure. N Eng J Med. 2021;384:117–28.”
5. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Eng J Med. 2021;384:129–39.
6. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and worsening heart failure. N Eng J Med. 2021;384:117–28.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.